Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
840.00    14.00 (1.69%)
Bid:
840.00
Ask:
848.00
Spread: 8.00 (0.952%)
Market Cap: £229.91m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Life Sciences Acquisition

8 Aug 2018 07:00

RNS Number : 1631X
Gooch & Housego PLC
08 August 2018
 

For immediate release

8 August 2018

 

 

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Life Sciences Acquisition

 

 Further enabling G&H's move into system based products

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components & systems, announces that it has acquired the entire issued share capital of VITL Ltd ('ITL" or "Integrated Technologies Limited") for a total consideration of up to £22.0 million. This acquisition expands the Company's presence in the life sciences sector and further enables G&H's move into system based products.

 

ITL

 

Founded in 1977, ITL is a UK based specialist in the design, development and manufacture of high-quality medical and in vitro diagnostic (IVD) devices.

 

ITL is a market leading supplier with an established group of long standing multi national customers. It provides full product development, design, manufacturing and after sale service for the commercialisation of medical diagnostic, analytical, precision electro-mechanical and laboratory instruments. ITL is headquartered in Ashford, Kent, with manufacturing sites in Ashford and Shanghai, China, plus a US client servicing capability based in Virginia, USA.

 

This acquisition enables G&H to take a significant step towards meeting its strategic objectives, including doubling the revenue of its life science business and accelerating the Company's move up the value chain, with all of ITL's sales coming from system based products. ITL's core group of electronic, software and mechanical engineers, provides an enhanced platform on which G&H can expand its systems capabilities.

 

Over time there are a number of potential benefits that will accrue from ITL becoming part of G&H. These include leveraging G&H's footprint in the US, China and Far East and combining the Company's photonic expertise with ITL's high level systems capability in order to provide a more attractive product offering to G&H's medical diagnostic customer base.

 

Terms of acquisition

 

The total consideration payable by G&H is up to £22.0 million. This comprises an initial cash consideration of £14.0 million, funded from existing resources, together with £1.4 million of new G&H shares. There is also a deferred contingent cash consideration of up to £8.0 million, based upon the performance of the business over the next two years. The Company has made an application to the London Stock Exchange for the 92,684 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will become effective on or around 14 August 2018.

 

The historical annual revenue of ITL was c.£10 million, adjusted operating profit was c.£1.5 million and the acquisition is expected to be earnings enhancing in the first full financial year of G&H's ownership. Historical gross assets were c£7 million.

 

 

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"This acquisition provides a key step towards achieving our strategic aims of establishing 'critical mass' in our life sciences business and moving up the value chain, through a more systems based product portfolio.

"It means we are able to continue to diversify our business, allow G&H access to new high growth markets, as well as reducing, still further, dependency on the historically cyclical micro-electronic sector.

"ITL is a high quality business, with a long standing customer base, excellent engineering capabilities and a strong financial track record. 

"We are very much looking forward to working with the management, staff and customers of ITL."

 

 

For further information contact: -

 

 

 

Mark Webster / Andrew Boteler

Gooch & Housego PLC

01460 256440

Mark Court/ Sophie Wills

Buchanan

020 7466 5000

Patrick Robb / David Anderson

Investec Bank plc

020 7597 5970

 

 

 

 

 

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQEVLBBVVFLBBQ
Date   Source Headline
9th Mar 20097:00 amRNSMarket Update
29th Jan 20094:04 pmRNSTrading Update
1st Dec 200810:56 amRNSDirector Share Dealing
25th Nov 200812:27 pmRNSPreliminary Results - Replacement
25th Nov 20087:00 amRNSPreliminary Results
5th Nov 20087:00 amRNSNotice of Results
10th Oct 20087:00 amRNSAcquisition of General Optics
9th Oct 20087:00 amRNSFull Year Trading Update
25th Sep 200811:47 amRNSInvestor and Analyst Site Visits
19th Sep 20083:11 pmRNSShare Option Purchase
4th Jul 20087:00 amRNSAcquisition of General Optics
24th Jun 20087:00 amRNSChange of NOMAD & Broker
17th Jun 20087:00 amRNSInterim Results
27th May 20087:00 amRNSIFRS
13th May 20086:00 amRNSNotice of Results
9th Apr 20087:00 amRNSTrading Update
28th Mar 20089:59 amRNSAnnual Report and Accounts
12th Mar 20084:37 pmRNSAdditional Listing
13th Feb 200811:00 amRNSAGM Statement
5th Feb 20087:01 amRNSVendor Appreciation Award
22nd Jan 20087:01 amRNSGlobal Integration
7th Jan 20088:53 amRNSAdditional Listing
7th Jan 20087:01 amRNSSIFAM Order
4th Jan 200812:32 pmRNSDirector Shareholding
21st Dec 20074:46 pmRNSHolding(s) in Company
21st Dec 20074:35 pmRNSAdditional Listing
7th Dec 20073:00 pmRNSLong Term Incentive Plan
3rd Dec 200712:20 pmRNSAdditional Listing
30th Nov 20073:44 pmRNSHolding(s) in Company
27th Nov 20077:00 amRNSAppointment
27th Nov 20077:00 amRNSPreliminary Results
15th Nov 20077:01 amRNSAppointment
29th Oct 20077:01 amRNSNotice of Results
4th Oct 20077:01 amRNSFull Year Trading Update
23rd Aug 20078:26 amRNSAdditional Listing
22nd Aug 20075:38 pmRNSDirector Shareholdings
17th Aug 20076:23 pmRNSAIM Rule 26
16th Aug 20072:12 pmRNSAdditional Listing
14th Aug 200712:36 pmRNSLTIP Awards
10th Aug 20075:18 pmRNSDirector Shareholdings
17th Jul 20074:16 pmRNSDirector of Sales Appointment
5th Jun 20077:02 amRNSInterim Results
31st May 20079:55 amRNSTotal Voting Rights
10th May 20079:58 amRNSHolding(s) in Company
9th May 20077:01 amRNSNotice of Results
8th May 20071:53 pmRNSAdditional Listing
8th May 20077:02 amRNSAcquisition
11th Apr 20077:01 amRNSTrading Update
8th Mar 20075:54 pmRNSHolding(s) in Company
14th Feb 20077:01 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.